Catabasis Pharmaceuticals is a company committed to finding innovative therapies to improve the lives of patients suffering from Duchenne muscular dystrophy. The company's lead program, edasalonexent, is currently in Phase 3 development and works by inhibiting the NF-kB protein. Catabasis's mission is to bring hope and transformative treatments to patients and their families.